Jan 27, 2022 / 01:00PM GMT
Operator
Good morning. Welcome to Taysha Gene Therapies GM2 Gangliosidosis Program Update Conference Call and Webcast. (Operator Instructions) As a reminder, this webcast is being recorded today, January 27, 2022.
I'll now turn the call over to Dr. Kimberly Lee, Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Kimberly Lee - Taysha Gene Therapies, Inc. - SVP of Corporate Communications & IR
Thank you. Good morning, and welcome to Taysha's GM2 Gangliosidosis Program Update Conference Call and Webcast. Earlier this morning, Taysha issued a press release reporting preliminary clinical safety and Hex A enzyme activity data for TSHA-101 and GM2 gangliosidosis. A copy of this press release is available on the company's website and through our SEC filings.
On this call, we will review the reported data and discuss next steps for our clinical development program.
Joining me on today's call are RA Session, II, Taysha's President, CEO and Founder; and Dr. Suyash Prasad, Chief Medical Officer and Head of
Taysha Gene Therapies Inc To Discuss TSHA-101 In GM2 Gangliosidosis Program Update Call Transcript
Jan 27, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers